INmune Bio Beheer

Beheer criteriumcontroles 2/4

De CEO INmune Bio is RJ Tesi, benoemd in Sep2015, heeft een ambtstermijn van 9.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.69M, bestaande uit 29.5% salaris en 70.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 7.01% van de aandelen van het bedrijf, ter waarde $ 7.57M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.1 jaar en 7.9 jaar.

Belangrijke informatie

RJ Tesi

Algemeen directeur

US$1.7m

Totale compensatie

Percentage CEO-salaris	29.5%
Dienstverband CEO	9.2yrs
Eigendom CEO	7.0%
Management gemiddelde ambtstermijn	9.1yrs
Gemiddelde ambtstermijn bestuur	7.9yrs

Recente managementupdates

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

Jul 12

Recent updates

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Nov 03

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Sep 30

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

Jul 12

INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors

Apr 05

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Mar 25

Analyse CEO-vergoeding

Hoe is RJ Tesi's beloning veranderd ten opzichte van INmune Bio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$41m
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$34m
Dec 31 2023	US$2m	US$501k	-US$30m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$1m	US$455k	-US$27m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	n/a	n/a	-US$33m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$3m	US$455k	-US$30m
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$300k	US$300k	-US$12m
Sep 30 2020	n/a	n/a	-US$11m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$1m	US$248k	-US$8m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$11m
Dec 31 2018	US$3m	US$120k	-US$12m

Compensatie versus markt: De totale vergoeding ($USD 1.69M ) RJ } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van RJ is gestegen terwijl het bedrijf verliesgevend is.

CEO

RJ Tesi (68 yo)

9.2yrs

Tenure

US$1,694,818

Compensatie

Dr. Raymond Joseph Tesi, MD, also known as RJ, serves as Director at Bexion Pharmaceuticals, Inc. Dr. Tesi is the Co-Founder of INmuneBio Inc. and has been its Chief Medical Officer and Chairman and serves...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Raymond Tesi	Co-Founder	9.2yrs	US$1.69m	7.01% $ 7.6m
David Moss	CFO, Treasurer & Secretary	9.2yrs	US$1.59m	5.8% $ 6.3m
Mark Lowdell	Chief Scientific Officer & Chief Manufacturing Officer	9.1yrs	US$150.24k	6.81% $ 7.4m
Joshua Schoonover	General Counsel	5.8yrs	geen gegevens	geen gegevens

9.1yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van INMB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Raymond Tesi	Co-Founder	9.2yrs	US$1.69m	7.01% $ 7.6m
Marcia Allen	Independent Director	5yrs	US$301.66k	geen gegevens
Scott Juda	Independent Director	6.7yrs	US$301.66k	0.32% $ 348.7k
James Ganjei	Independent Director	8.2yrs	US$301.66k	0.080% $ 86.7k
Timothy Schroeder	Independent Director	7.9yrs	US$301.26k	0.37% $ 400.2k

7.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INMB wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.9 jaar).

INmune Bio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CFO, Treasurer & Secretary recently bought US$53k worth of stock

Co-Founder recently bought US$98k worth of stock

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

INmune Bio, Inc., Annual General Meeting, Jul 19, 2024

Independent Director recently bought US$246k worth of stock

Insufficient new directors

Recent updates

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

New major risk - Revenue and earnings growth

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)

INmune Bio, Inc. to Report Q3, 2024 Results on Oct 31, 2024

CFO, Treasurer & Secretary recently bought US$53k worth of stock

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Co-Founder recently bought US$98k worth of stock

INmune Bio, Inc. Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

INmune Bio, Inc. has filed a Follow-on Equity Offering.

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Consensus EPS estimates upgraded to US$2.26 loss

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™? on Proteins That Regulation Synapse in Alzheimer's Patients

INmune Bio, Inc. to Report Q2, 2024 Results on Aug 01, 2024

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial

INmune Bio, Inc., Annual General Meeting, Jul 19, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.67 loss per share (vs US$1.52 loss in FY 2022)

Consensus EPS estimates fall by 24%

INmune Bio, Inc. to Report Q1, 2024 Results on May 09, 2024

INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $9.70224 million.

Independent Director recently bought US$246k worth of stock

Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 35%, EPS upgraded

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

INmune Bio, Inc. to Report Q4, 2023 Results on Mar 28, 2024

INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro

Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’S Disease Program

New minor risk - Share price stability

Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?

INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA

Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe

Consensus revenue estimates increase by 30%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Inmune Bio, Inc. Announces Update Regarding Patent Claims Covering Inb16 Cell Line

INmune Bio, Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease Conference

INmune Bio, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Inmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’S Disease

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Consensus revenue estimates increase by 51%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. to Report Q2, 2023 Results on Aug 07, 2023

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

INmune Bio, Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. Announces Pre-Clinical Data to Support Pioneering Approach to Treating Duchenne Muscular Dystrophy

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 Expressing HER2+ Breast Cancer

Insufficient new directors

INmune Bio, Inc. Focuses on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

Price target decreased to US$14.33

Inmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of Xpro1595 in Mild Alzheimer’S Disease

Consensus revenue estimates increase by 24%

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.55 loss in 3Q 2021)

INmune Bio, Inc. to Report Q3, 2022 Results on Nov 02, 2022

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune